News & Updates

Tirzepatide reduces CV death, worsening HF in obese patients with HFpEF

18 Dec 2024 by

Treatment with tirzepatide reduced the risk of cardiovascular (CV) death and worsening heart failure (HF) in patients with HF with preserved ejection fraction (HFpEF) and obesity, according to the SUMMIT trial presented at AHA 2024.

Tirzepatide reduces CV death, worsening HF in obese patients with HFpEF

18 Dec 2024

Chlorthalidone no better than hydrochlorothiazide for kidney health

17 Dec 2024 by

In the treatment of patients with hypertension, the use of chlorthalidone does not appear to yield superior kidney outcomes when compared with hydrochlorothiazide but is associated with an increased risk of hypokalemia, as reported in a study.

Chlorthalidone no better than hydrochlorothiazide for kidney health

17 Dec 2024

DMT discontinuation poses risk of recurrence even in patients with long-term stable MS

17 Dec 2024

For people with long-term stable multiple sclerosis (MS) who use disease-modifying therapy (DMT) in the first-line setting, discontinuation spells an increased hazard of inflammatory disease activity recurrence, as shown in a study.

DMT discontinuation poses risk of recurrence even in patients with long-term stable MS

17 Dec 2024

Statins help improve outcomes in hospitalized COVID-19 patients

16 Dec 2024

In patients hospitalized for COVID-19, use of statins prior to admission is predictive of improved outcomes and lower inflammation, according to a study.

Statins help improve outcomes in hospitalized COVID-19 patients

16 Dec 2024

Add-on mifepristone for early pregnancy loss lowers chances of treatment failure

16 Dec 2024

In the treatment of women with early pregnancy loss, adding mifepristone to misoprostol helps reduce the incidence of treatment failure as compared with misoprostol alone, according to a retrospective study.

Add-on mifepristone for early pregnancy loss lowers chances of treatment failure

16 Dec 2024

Psilocybin: A new paradigm for treating postpandemic depression?

16 Dec 2024 by

Healthcare workers who developed depression in the course of frontline work during the COVID-19 pandemic experienced substantial reductions in symptoms following psilocybin treatment, as shown in a small randomized clinical trial.

Psilocybin: A new paradigm for treating postpandemic depression?

16 Dec 2024

Fostamatinib of no benefit in COVID-19 patients with hypoxemia

15 Dec 2024

In the treatment of hospitalized adults with COVID-19 and hypoxemia, the use of the spleen tyrosine kinase inhibitor fostamatinib does not appear to have any positive effect on the number of oxygen-free days as compared with placebo, according to the results of a phase III trial.

Fostamatinib of no benefit in COVID-19 patients with hypoxemia

15 Dec 2024

No increased risk of brain bleed with DOAC vs antiplatelet therapy in AF patients

15 Dec 2024

In the treatment of patients with atrial fibrillation (AF), direct oral anticoagulants (DOACs) do not contribute to an increased risk of intracranial haemorrhage compared with antiplatelet therapy, according to the results of a systematic review and meta-analysis.

No increased risk of brain bleed with DOAC vs antiplatelet therapy in AF patients

15 Dec 2024

Salbutamol may lower risk, improve prognosis of prostate cancer

14 Dec 2024

The incidence of prostate cancer is reduced among individuals treated with salbutamol, a short-acting beta-2 adrenergic agonist, according to a study.

Salbutamol may lower risk, improve prognosis of prostate cancer

14 Dec 2024

$Novel EZH1/2 dual inhibitor shows activity against relapsed/refractory T-cell lymphoma$

Novel EZH1/2 dual inhibitor shows activity against relapsed/refractory T-cell lymphoma

14 Dec 2024

Dual inhibition of EZH1/2 with valemetostat appears to induce responses in patients with relapsed or refractory peripheral T-cell lymphoma while having a manageable safety profile, according to the results of a single-arm phase II trial.

Novel EZH1/2 dual inhibitor shows activity against relapsed/refractory T-cell lymphoma

14 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Tirzepatide reduces CV death, worsening HF in obese patients with HFpEF

Tirzepatide reduces CV death, worsening HF in obese patients with HFpEF

Chlorthalidone no better than hydrochlorothiazide for kidney health

Chlorthalidone no better than hydrochlorothiazide for kidney health

DMT discontinuation poses risk of recurrence even in patients with long-term stable MS

DMT discontinuation poses risk of recurrence even in patients with long-term stable MS

Statins help improve outcomes in hospitalized COVID-19 patients

Statins help improve outcomes in hospitalized COVID-19 patients

Add-on mifepristone for early pregnancy loss lowers chances of treatment failure

Add-on mifepristone for early pregnancy loss lowers chances of treatment failure

Psilocybin: A new paradigm for treating postpandemic depression?

Psilocybin: A new paradigm for treating postpandemic depression?

Fostamatinib of no benefit in COVID-19 patients with hypoxemia

Fostamatinib of no benefit in COVID-19 patients with hypoxemia

No increased risk of brain bleed with DOAC vs antiplatelet therapy in AF patients

No increased risk of brain bleed with DOAC vs antiplatelet therapy in AF patients

Salbutamol may lower risk, improve prognosis of prostate cancer

Salbutamol may lower risk, improve prognosis of prostate cancer

Novel EZH1/2 dual inhibitor shows activity against relapsed/refractory T-cell lymphoma

Novel EZH1/2 dual inhibitor shows activity against relapsed/refractory T-cell lymphoma